您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > NTP42
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
NTP42
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
NTP42图片
CAS NO:2055599-51-2
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品介绍
NTP42 是一种血栓素 (TXA2) 受体拮抗剂，拮抗用前列腺素受体 (TP) 激动剂 U46609 刺激细胞后 TP 介导的 [Ca2+] 流通，IC50 为 3.278 nM。NTP42 可用于治疗肺动脉高压 (PAH)。
Cas No.2055599-51-2
Canonical SMILESO=S(C1=CC(C#N)=CC=C1OC2=CC(C3=CC=C(OC(F)F)C=C3)=CC=C2)(NC(NC(C)(C)C)=O)=O
分子式C25H23F2N3O5S
分子量515.53
溶解度DMSO: 31.25 mg/mL (60.62 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca2+] mobilization following stimulation of cells with the alternative TP agonist U46609[1]. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH)[2].

NTP42 (0.25 mg/kg BID) is potent in a monocrotaline (MCT)-induced PAH rat model (28-day drug treatment is initiated within 24 h post-MCT) in haemodynamic assessments. NTP42 reduces the MCT-induced PAH, including mean pulmonary arterial pressure (mPAP) and right systolic ventricular pressure (RSVP). Moreover, NTP42 is superior to Sildenafil and Selexipag in significantly reducing pulmonary vascular remodelling, inflammatory mast cell infiltration and fibrosis in MCT-treated animals[2]. Animal Model: Male Wistar-Kyoto rats[2]

[1]. B. Therese KINSELLA, et al. Thromboxane receptor antagonists. WO2016203314A1. [2]. Eamon Mulvaney, et al. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.